122 patents currently held

30 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2029. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Oct 2029

Next term end

112

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026202720282029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Antibodies Directed Against ICOS and Uses Thereof US 9,376,493

The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2032.

Ends Oct 2032 · High confidence Also notable

Compounds for the Treatment of Autism US 9,415,028

Cited by 14 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.

Ends Jan 2031 · High confidence Also notable

TAFA4 Compounds and Uses Thereof for Treating Pain US 9,884,088

Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2034.

Ends May 2034 · High confidence

Formerly held, still cited

Notable

Method and Computing System for Modelling a Primate Brain US 11,562,253

Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.

now held by Max-Planck-Gesellschaft Zur Förderung der Wissenschaften E.V.

Ends Nov 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 23, 2026
The maintenance fee for Novel Immunoadjuvant Compounds and Uses Thereof (US 9,061,066) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
2 fees due Jan 4 to 16, 2027 · next Jan 4
1 fee due Feb 1, 2027
The maintenance fee for Compositions and Methods for Cancer Imaging and Radiotherapy (US 11,712,486) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
4 fees due Mar 3 to 24, 2027 · next Mar 3
1 fee due Apr 15, 2027
The maintenance fee for Non-Volatile Memory Allowing a High Integration Density (US 10,446,564) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
2 fees due May 19 to 21, 2027 · next May 19
1 fee due Jun 17, 2027
The maintenance fee for Methods and Systems for Optical Functionalisation of a Sample Made of Semiconductor Material (US 10,509,168) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
1 fee due Jul 16, 2027
The maintenance fee for A Buffer Memory Adapted to Implment Calculations Having Operands as Data (US 11,875,848) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
3 fees due Aug 6 to 27, 2027 · next Aug 6
4 fees due Sep 3 to 29, 2027 · next Sep 3
5 fees due Oct 2 to 30, 2027 · next Oct 2
1 fee due Nov 3, 2027
The maintenance fee for Peptide Derivatives and Use Thereof as Carriers for Molecules in the Form of Conjugates (US 9,328,143) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

3 of the patents on this record were granted since Aug 16, 2026
8 terms have ended since Aug 16, 2026

What they patent

The 5 largest of its 112 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Antibodies Directed Against ICOS and Uses Thereof	6 in force	to Jul 2033
ANTI-BTN3A Antibodies and Their Use in Treating Cancer or Infectious Disorders	2 in force	to Jul 2041
Regulatory T Cells Genetically Modified for the Lymphotoxin Alpha Gene and Uses Thereof	2 in force	to Sep 2039
Compositions and Methods for Cancer Imaging and Radiotherapy	2 in force	to Jan 2038
Human Soluble CD146, Preparation and Uses Thereof	2 in force	to Nov 2030

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,328,143	Peptide Derivatives and Use Thereof as Carriers for Molecules in the Form of Conjugates held by Centre National De La Recherche Scientifique In force Term ends Oct 20, 2029 · High confidence	In force	Term ends Oct 20, 2029	High confidence
US 8,729,029	Peptide Derivatives and Use Thereof as Carriers for Molecules in the Form of Conjugates In force Term ends Dec 13, 2029 · High confidence	In force	Term ends Dec 13, 2029	High confidence
US 8,877,716	Peptide Derivatives, Preparation and Uses Thereof In force Term ends Dec 13, 2029 · High confidence	In force	Term ends Dec 13, 2029	High confidence
US 9,297,044	Fibrosis Susceptibility Gene and Uses Thereof In force Term ends Feb 18, 2030 · High confidence	In force	Term ends Feb 18, 2030	High confidence
US 10,774,153	Human Soluble CD146, Preparation and Uses Thereof In force Term ends Mar 27, 2030 · High confidence	In force	Term ends Mar 27, 2030	High confidence
US 8,541,189	Method for Measuring the Plasmine Activity of Microparticles Present in a Sample of Blood or a Blood Component In force Term ends Aug 18, 2030 · High confidence	In force	Term ends Aug 18, 2030	High confidence
US 9,605,048	Human Soluble CD146, Preparation and Uses Thereof In force Term ends Nov 29, 2030 · High confidence	In force	Term ends Nov 29, 2030	High confidence
US 9,415,028	Compounds for the Treatment of Autism held by Inserm (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille and Chu de Brest In force Term ends Jan 13, 2031 · High confidence	In force	Term ends Jan 13, 2031	High confidence
US 8,853,158	Methods for the Treatment of a Feeding Disorder with Onset During Neonate Development Using an Agonist of the Oxytocin Receptor held by Institut National de la Sante et de la Recherche Medicale (Inserm), Chu de Toulouse and Universite d'Aix-Marseille In force Term ends May 25, 2031 · High confidence	In force	Term ends May 25, 2031	High confidence
US 9,061,066	Novel Immunoadjuvant Compounds and Uses Thereof held by Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille and Baylor Research Institute In force Term ends Jul 14, 2031 · High confidence	In force	Term ends Jul 14, 2031	High confidence

10 of 122 patents shown.

Pro members see all 122.

Pro members: see all 122 patents

Also on record, not counted in the 122: 30 patents in force now held by others · 106 patents ended · 107 applications pending · 138 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Universite d'Aix Marseille